Here you'll find new developments in the management of multiple myeloma.
What will be the best use of new immunomodulatory agents such as thalidomide and bortezomib? Which new genetic or clinical markers will emerge to improve risk stratification for multiple myeloma?
With offerings from a diversity of authoritative online resources, this is the best place to remain up to date with rapid changes in science and clinical practice that affect multiple myeloma management.
Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the burden (the number of incident cases) increased.[1] More »
High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma. More »
No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid), ASCT has a diminished role in the front-line treatment of older patients with myeloma. More »
Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin. More »
The Takeda Oncology Company announced that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for bortezomib (Velcade), which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial... More »
The management of older patients with cancer is historically challenging because of a lack of prospective data regarding the appropriate management of this population. In this review, we address some of the issues and challenges surrounding the treatment of older cancer patients, including the withholding of medically appropriate treatment based on chronologic age, the historical omission of elderly from clinical trials, and the impact of geriatric assessment, and age-related changes in... More »
More is better, at least when it comes to treatments for multiple myeloma. Studies from Spanish and Italian investigators showed that upfront use of four drugs improves durable responses and progression-free survival in elderly patients. More »
Research presented at the 51st Annual ASH Meeting explored optimal induction therapies for managing multiple myeloma and a potential first-line therapy for patients with non-Hodgkin lymphoma (NHL). More »
